PsychoGenics Inc. provides preclinical contract research and drug discovery services. The company offers various in vivo tests in the areas of animal models, anxiety, cognition, depression and sexual function, drug abuse liability, epilepsy, injury and pain, micro-dialysis, motor function, neurogenesis, neurological disorders, schizophrenia and mania, and other areas; and in vitro and ex vivo tests in the areas of electrophysiology, neurochemistry, quantitative western blots and quantitative RT-PCR and ELISA, and receptor occupancy. It also creates a range of drug candidates to address various CNS disorders, such as ADHD, cognitive impairment, depression, psychiatric and neurodegenerative di...
765 Old Saw Mill River Road
Tarrytown, NY 10591
Founded in 1999
PsychoGenics Receives License to the Cntnap2 Knockout Mouse Model from the Weizmann Institute
Jun 16 14
PsychoGenics Inc. announced that it has received a license to use the Cntnap2 knockout mouse from Yeda R&D Co. Ltd., the technology transfer company of the Weizmann Institute of Science. The CNTNAP2 gene encodes for Contactin Associated Protein 2 (Caspr2), a member of the neurexin family of cell recognition molecules. Mutations in this gene are associated with schizophrenia, autism, ADHD and language impairment. The Cntnap2 homozygous null mice were developed by Dr. Elior Peles. This model shows characteristics of Autism Spectrum Disorder (ASD) and ADHD such as deficits in a social test, hyperactivity in novel environments and changes in gait. Published reports describe reduced neonatal vocalizations, increased repetitive behavior and seizures, neuronal migration deficits with reduced interneuron number and asynchronous firing. In addition, pharmacological treatment with the antipsychotic risperidone improved repetitive behavior. Aspects of this phenotype were confirmed and expanded at PsychoGenics. This novel model of ASD promises to advance drug screening and development for ASD and associated disorders.